Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | ENPP3 | O14638 | 5/20 | 0.46 |
| ▸ | ENPP1 | P22413 | 5/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.45 |
| ▸ | CDC42 | P60953 | 1/20 | 0.45 |
| ▸ | RAC1 | P63000 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.45 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2835298 | 1.00 | ADAMTS4 (0.55) | ADAMTS4TDP1PTGS2MAPTNPC1 | |
| SCHEMBL1345327 | 1.00 | ADAMTS4 (0.55) | ADAMTS4TDP1PTGS2MAPTNPC1 | |
| SCHEMBL1824672 | 0.92 | TDP1 (0.53) | ADAMTS4TDP1PTGS2MAPTNPC1 | |
| SCHEMBL1827128 | 0.88 | TDP1 (0.51) | ADAMTS4TDP1MAPTNPC1RAB9A | |
| SCHEMBL2838458 | 0.88 | MEN1 (0.52) | ADAMTS4PTGS2MAPTAKR1C3AKR1C2 | |
| SCHEMBL2834868 | 0.87 | ADAMTS4 (0.52) | ADAMTS4TDP1PTGS2MAPTNPC1 | |
| SCHEMBL2832246 | 0.84 | TDP1 (0.48) | ADAMTS4TDP1MAPTNPC1RAB9A | |
| SCHEMBL1825604 | 0.84 | TDP1 (0.57) | ADAMTS4TDP1MAPTNPC1RAB9A | |
| SCHEMBL2834837 | 0.84 | PTGS1 (0.64) | ADAMTS4TDP1PTGS2MAPTAKR1C3 | |
| SCHEMBL1826737 | 0.83 | TDP1 (0.47) | ADAMTS4TDP1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063242-B2 | for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion | DOMPE PHA.R.MA S.P.A. (IT) | 2011-11-22 | — | — | US | claimed |
| EP-1455773-B1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-04 | — | — | EP | claimed |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2005-02-17 | — | — | US | claimed |
| EP-1455773-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | claimed |
| WO-2003043625-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-05-30 | — | — | WO | claimed |
| US-8063242-B2 | for treatment of neutrofil-dependent pathologies such as psoriasis, ulcerative colitis, melanoma, chronic obstructive pulmonary disease (COPD), bollous pemphigo, rheumatoid arthritis, idiopathic fibrosis, glomerulonephritis; prevention and treatment of damages caused by ischemia and reperfusion | DOMPE PHA.R.MA S.P.A. (IT) | 2011-11-22 | — | — | US | disclosed |
| EP-2229942-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | Dompe S.p.A. (IT) | 2010-09-22 | — | — | EP | disclosed |
| EP-1455773-B1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA R MA SPA RES & MFG (IT) | 2009-11-04 | — | — | EP | disclosed |
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2005-02-17 | — | — | US | disclosed |
| EP-1455773-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Dompé S.P.A. (IT) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003043625-A1 | 2-ARYL-PROPIONIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE S.P.A. (IT) | 2003-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038119-A1 | 2-Aryl-propionic acids and pharmaceutical compositions containing them | CXCR2, FPR1, CCR2 | ADAMTS4 4596/4885TDP1 3939/4885PTGS2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.